The COVID-19 pandemic has added an additional layer of complexity to the management of patients with rheumatic disease or those on immunosuppressive therapy. This has been compounded by the lack of specific data on SARS-CoV-2 infection in this population, as well as shortages of hydroxychloroquine. Dr. Shikha Mittoo (@rheumatlarge) is a community-based rheumatologist appointed at University Health Network in Toronto, Canada, with a particular interest in inflammatory arthritis and the impact of lung disease on clinical outcomes in rheumatic disease. She served as the co-research director for the Interstitial Lung Disease Program at University Health Network, and as adjunct assistant professor at the University of Toronto. Dr. Mittoo will be taking your questions on fever syndromes, hyperinflammation, and cytokine storms associated with COVID-19; clues to differentiating rheumatic disease, rheumatic flares, and COVID-19 infection with rheumatic features; and the management strategies she's using for her patients during the pandemic. Questions for Dr. Mittoo? Ask in the comments below. She'll be answering on April 29, 2020. Follow this case for updates.